MedPath

Alternation of Non-alcoholic Fatty Liver Disease (NAFLD) and Cardiovascular Risks After Liftestyle Modification: A Ultrasound Attenuation Imaging-Based Study

Not Applicable
Terminated
Conditions
Non-alcoholic Fatty Liver Disease
Interventions
Behavioral: Conventional care (control)
Behavioral: Dietitian led life style modification intervention
Registration Number
NCT04440540
Lead Sponsor
Chinese University of Hong Kong
Brief Summary

The prevalence of obesity has significantly increased over the last few decades. The excessive fat accumulation in undesired areas in obese patients may lead to various complications, such as cardiovascular diseases and Non-alcoholic fatty liver disease (NAFLD) defined by intrahepatic triglycerides (IHTG) content higher than 5.5%. In Hong Kong, the incidence rate of NAFLD is as high as approximately 13.5%, while 60.5% of obese subjects suffer from NAFLD. NAFLD is found to be a well-established risk factor for chronic kidney disease, type 2 diabetes, and cardiovascular disease. Moreover, obesity is a strong independent risk factor for development of atherosclerosis. It also plays important role in pathogenesis of dyslipidaemia, insulin resistance, hypertension. Both NAFLD and cardiovascular risks can be reversed. Lifestyle modification program(LMP) including diet control and routine exercise has been widely recommended to patients with mild to moderate obesity. It is vital to have a non-invasive, non-ionizing, low cost, accessible or widely available and yet accurate assessment tool to diagnose NAFLD and some cardiovascular risk parameters and serially monitor changes to assess the efficacy of LMP. Ultrasound meets these requirements. To the best of our knowledge there has been no prior study similar to this one. In this study, we aim to assess and validate the diagnostic accuracy of a novel ultrasound attenuation imaging method for NAFLD, and to evaluate the effectiveness of LMP in reversal of NAFLD and reduction of cardiovascular risks in moderate obesity.

A total of forty moderate obese patients with NAFLD will be recruited in this study, divided into lifestyle modification program group(n=20) and usual care group(n=20). All subjects will undergo dietary assessment based on 3-day diet record and power of food scale. Demographic data will be recorded, consisted of age, weight, height, waist circumference, BMI, and so on. Ultrasound attenuation imaging (ATI) will be performed to measure tissue attenuation coefficient so as to evaluate liver steatosis and liver fibrosis stage. Meanwhile, magnetic resonance imaging (MRI) will be carried out, which include cardiovascular risks measurement, liver proton density fat fraction (PDFF), volume quantification of abdominal white adipose tissue, liver inflammation and fibrosis assessment. Biochemistry tests will be conducted as supplementary for assessment of NAFLD and cardiovascular risks, comprising liver function test, lipid, fasting glucose, etc.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
10
Inclusion Criteria
  • With age range of 18-65 years.
  • With diagnosis of NAFLD.
  • BMI =27.5- 32.4kg/m2 for moderate obesity (Asian population)
  • Written consent form obtained.
Exclusion Criteria
  • Other kind of hepatic diseases or under medications known to affect liver fat accumulation.
  • Excessive alcohol consumption (>20g/d for men and >10g/d for women).
  • Subjects using thyroid hormones, oestrogens, amiodarone, steroids, tamoxifen and beta blockers (e.g. propranolol).
  • Body weight >250kgs and or/ waist circumference > 150cm.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
usual care group (control)Conventional care (control)-
lifestyle modification program groupDietitian led life style modification intervention-
Primary Outcome Measures
NameTimeMethod
cardiovascular risks1 year

cardiovascular risks reflected by Intima-media thicknesses of both carotid arteries

intrahepatic triglycerides (IHTG) content1 year

change of IHTG content in NAFLD assessed by ultrasound

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

The Chinese University of Hong Kong, Prince of Wale Hospital

🇭🇰

Hong Kong, Shatin, Hong Kong

© Copyright 2025. All Rights Reserved by MedPath